The company remains pre-revenue with operating expenses reaching $1.6 million in 2025Q3, reflecting a persistent lack of commercialization and ongoing operational burn.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 7.18M | 5.54M | 631.32K | 574.37K | 1.11M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 6.67M | 5.54M | 631.32K | 574.37K | 1.11M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 509.85K | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.18M | -5.54M | -631.32K | -574.37K | -1.11M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -777.56% | -9.91% | 48.21% | - |
| EBITDA | -7.5M | -5.79M | -631.24K | -574.23K | -1.11M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | -81.47% | -817.83% | -9.93% | 48.22% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 |
| EBIT | -7.5M | -5.79M | -631.24K | -574.23K | -1.11M |
| Net Interest Income | -3.79M | -356.6K | -76.21K | -24.37K | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.79M | 356.6K | 76.21K | 24.37K | 0 |
| Other Income/Expense | -4.11M | -610.14K | -76.14K | -24.22K | 44 |
| Pretax Income | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | -168.2% | -769.36% | -18.19% | 46.03% | - |
| Net Income (Continuing) | -11.29M | -6.15M | -707.46K | -598.59K | -1.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19 | -0.32 | -0.00 | -0.00 | -0.00 |
| EPS Growth % | -49.77% | - | - | - | - |
| EPS (Basic) | - | -0.32 | -0.00 | -0.00 | -0.00 |
| Diluted Shares Outstanding | 59.42M | 19.25M | 1.04B | 1.04B | 1.04B |
| Basic Shares Outstanding | 59.42M | 19.25M | 1.04B | 1.04B | 1.04B |
| Dividend Payout Ratio | - | - | - | - | - |
Imminent liquidity insolvency risk
As indicated by the company's financial filings, KLTO remains a pre-revenue entity with no commercialized products, meaning that revenue growth metrics are currently non-existent and the firm's trajectory is defined entirely by its ability to advance its clinical pipeline rather than top-line expansion.
The absence of revenue underscores the binary nature of the company's business model, where value is derived from clinical milestones rather than operational sales. Investors should monitor the transition from research-stage activities to potential licensing agreements, as the current lack of income streams necessitates constant external capital.
According to the latest quarterly income statements, KLTO's operating expenses have fluctuated significantly, with SG&A costs reaching $1.6 million in 2025Q3, reflecting the high non-discretionary burn rate required to maintain public listing status and support early-stage preclinical development efforts.
The cost structure is heavily weighted toward administrative overhead, which appears to be consuming the majority of the company's limited resources. The recent initiation of R&D spending suggests a pivot toward clinical development, yet this shift further pressures the firm's already precarious cash position.
Based on reported figures, KLTO recorded a net loss of $2.9 million in 2025Q3, highlighting the persistent disconnect between the company's high operating expenses and its lack of revenue, which complicates the assessment of earnings quality in a pre-commercial biotech environment.
The recurring net losses are characteristic of early-stage gene therapy firms, yet the magnitude of these losses relative to the company's reported cash reserves warrants extreme caution. The volatility in quarterly net income appears driven by fluctuating SG&A and sporadic R&D outlays rather than any underlying operational efficiency.
As highlighted in recent financial disclosures, the company's reported cash and equivalents of $63,741 suggest a critical liquidity shortfall that may impede the firm's ability to sustain its current R&D trajectory without immediate and potentially highly dilutive capital raises.
The disparity between the company's quarterly burn rate and its available cash reserves indicates a high probability of insolvency risk in the near term. Market participants should consider whether the current valuation accounts for the high likelihood of significant equity dilution required to fund ongoing preclinical studies.
Quick answers to the most common questions about buying KLTO stock.
For fiscal year 2024, Klotho Neurosciences, Inc. (KLTO) reported total revenue of $0.0M.
Klotho Neurosciences, Inc. (KLTO) reported a net loss of $6.2M for the fiscal year ending 2024.